Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
D Capodanno, DL Bhatt, JW Eikelboom… - Nature Reviews …, 2020 - nature.com
Advances in antiplatelet therapies for patients with cardiovascular disease have improved
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …
[PDF][PDF] Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
D Capodanno, DL Bhatt, JW Eikelboom, KAA Fox - academia.edu
Although advances in antiplatelet therapies for patients with cardiovascular disease have
improved overall patient outcomes, balancing ischemic and bleeding risks remains …
improved overall patient outcomes, balancing ischemic and bleeding risks remains …
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
C Davide, DL Bhatt, JW Eikelboom… - Nature Reviews …, 2020 - search.proquest.com
Advances in antiplatelet therapies for patients with cardiovascular disease have improved
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …
[引用][C] Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
D Capodanno, DL Bhatt… - Nature Reviews …, 2020 - tobias-lib.ub.uni-tuebingen.de
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in
cardiovascular disease Dual-pathway inhibition for secondary and tertiary antithrombotic …
cardiovascular disease Dual-pathway inhibition for secondary and tertiary antithrombotic …
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
D Capodanno, DL Bhatt… - Nature reviews …, 2020 - pubmed.ncbi.nlm.nih.gov
Advances in antiplatelet therapies for patients with cardiovascular disease have improved
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …
[PDF][PDF] Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
D Capodanno, DL Bhatt, JW Eikelboom, KAA Fox - documentserver.uhasselt.be
Although advances in antiplatelet therapies for patients with cardiovascular disease have
improved overall patient outcomes, balancing ischemic and bleeding risks remains …
improved overall patient outcomes, balancing ischemic and bleeding risks remains …
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
D Capodanno, DL Bhatt, JW Eikelboom… - Nature Reviews …, 2020 - diva-portal.org
Advances in antiplatelet therapies for patients with cardiovascular disease have improved
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease.
D Capodanno, DL Bhatt, JW Eikelboom… - Nature reviews …, 2020 - europepmc.org
Advances in antiplatelet therapies for patients with cardiovascular disease have improved
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …
[引用][C] Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
D Capodanno, DL Bhatt, JW Eikelboom… - Nature Reviews …, 2020 - cir.nii.ac.jp
[引用][C] Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
D Capodanno, DL Bhatt… - Nature Reviews …, 2020 - ub01.uni-tuebingen.de
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in
cardiovascular disease Dual-pathway inhibition for secondary and tertiary antithrombotic …
cardiovascular disease Dual-pathway inhibition for secondary and tertiary antithrombotic …